Clinical trials: Placebo Group
Coronary Heart Disease (CHD)
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
- Trial name
- GOLDILOX (NCT04610892)
- Testing
- MEDI6570
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Coronary Heart Disease
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
This 2 arm study will investigate the efficacy and safety of RO4607381 in patients with coronary heart disease, or CHD risk equivalent.
- Trial name
- NCT00353522
- Testing
- dalcetrapib
- Where
- 17 sites in United States, Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
ADHD
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
- Trial name
- NCT03172481
- Testing
- PRC-063 oral capsules
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- Purdue Pharma, Canada
Plaque Psoriasis
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06602219
- Testing
- LY4100511
- Where
- 58 sites in United States, Canada and 5 more
- Volunteers
- 222 people
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Atrophy, Vaginal Diseases
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
- Trial name
- NCT00276094
- Testing
- Ospemifene 30 mg, Ospemifene 60 mg, Nonhormonal vaginal lubricant
- Volunteers
- 826 people
- Sponsor
- Shionogi
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
- Trial name
- NCT02971839
- Testing
- VX-561, IVA
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy
Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers
Investigation of safety and tolerability of BI 655088 following intravenous infusion of single rising doses and exploration of the pharmacokinetics and pharmacodynamics of BI 655088 after single dosing
- Trial name
- NCT02696616
- Testing
- BI 655088
- Where
- Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects…
- Trial name
- NCT01165138
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 70 sites in United States, Germany and 4 more
- Volunteers
- 612 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects.
- Trial name
- NCT02130635
- Testing
- GSK2269557 100 MCG, GSK2269557 500 MCG
- Where
- 2 sites in Germany
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Diabetic Neuropathy
Study of DA-9801 to Treat Diabetic Neuropathy
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
- Trial name
- NCT01822925
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- 14 sites in United States
- Volunteers
- 128 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Uterine Myomas
PGL4001 Versus Placebo in Uterine Myomas
This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women…
- Trial name
- PEARLI (NCT00755755)
- Testing
- PGL4001 (ulipristal) and iron
- Where
- 38 sites in Czechia, Hungary and 4 more
- Volunteers
- 241 people
- Sponsor
- PregLem SA
Atopic Dermatitis (AD)
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01979016
- Testing
- Dupilumab, Background treatment
- Where
- 4 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Cluster Headache
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
The purpose of the current study is to evaluate the efficacy and safety of Fremanezumab (TEV-48125), in the prevention of CCH in adult participants.
- Trial name
- NCT02964338
- Testing
- Fremanezumab
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 259 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hypertension
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo.
- Trial name
- NCT00430638
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary
- Where
- 29 sites in United States
- Volunteers
- 278 people
- Sponsor
- Daiichi Sankyo
Cervical Dystonia, Spasmodic Torticollis
Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
To evaluate efficacy and safety of E2014 (2500U, 5000U, 10000U, placebo) in a multicenter, randomized, double-blind, parallel group comparative study by intramuscularly administering to patients with spasmodic torticollis.
- Trial name
- NCT00165776
- Testing
- BOTULINUM TOXIN TYPE B
- Where
- 21 sites in Japan
- Volunteers
- 133 people
- Sponsor
- Eisai Co., Ltd.
Acute Upper Respiratory Infections
Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections
Purpose of the study: To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.
- Trial name
- NCT03162458
- Testing
- Anaferon for children (liquid dosage form)
- Where
- 7 sites in Russia
- Volunteers
- 142 people
- Sponsor
- Materia Medica Holding
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with major depressive disorder.
- Trial name
- NCT01355081
- Testing
- Vortioxetine
- Where
- 32 sites in Japan
- Volunteers
- 366 people
- Sponsor
- Takeda
Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor…
- Trial name
- NCT01556165
- Testing
- rasagiline
- Where
- 15 sites in China
- Volunteers
- 130 people
- Sponsor
- H. Lundbeck A/S
Restless Legs Syndrome
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS).
- Trial name
- CONCORD (NCT01668667)
- Testing
- GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg
- Where
- 42 sites in United States
- Volunteers
- 501 people
- Sponsor
- XenoPort, Inc.
Non-alcoholic Steatohepatitis
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
This is a double-blind, placebo-controlled study in adults with non-alcoholic steatohepatitis and Type 2 Diabetes Mellitis on stable dose of metformin monotherapy.
- Trial name
- NCT03969719
- Testing
- PF-06835919
- Where
- 106 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.